DelveInsight’s ‘Degenerative Disc Disease Pipeline Insight 2023‘ report provides comprehensive global coverage of pipeline Degenerative Disc Disease therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Degenerative Disc Disease pipeline domain.

For Degenerative Disc Disease emerging drugs, the Degenerative Disc Disease pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

Key Takeaways from the Degenerative Disc Disease Pipeline Report 

• DelveInsight’s Degenerative Disc Disease Pipeline analysis depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Degenerative Disc Disease treatment. 
• The leading Degenerative Disc Disease companies include Spine BioPharma, Inc., Angitia Biopharmaceuticals, Mesoblast, Ltd., BioRestorative Therapies, DiscGenics, Inc., Biosplice Therapeutics, Notogen, AnGes, Inc., FibroGenesis, Genequine Biotherapeutics, Causeway Therapeutics, Boehringer Ingelheim, SpineOvations, BIOPHARM GmbH, Yuhan, Histogen Inc., and others are evaluating their lead assets to improve the Degenerative Disc Disease treatment landscape.
• Key Degenerative Disc Disease pipeline therapies in various stages of development include  SB-01, AGA111, Rexlemestrocel-L, BRTX-100, IDCT, Lorecivivint, AMG0103, CybroCell,  GQ-401, CWT 002, DiscSeal, rhGDF-5, HST 004, and others.
• In January 2023, VySpine, that it has received 510(k) clearance from the FDA for its LumiVy NanoVy Ti Lumbar IBF System, which is indicated for intervertebral body fusion for use at either one level or two contiguous levels in the lumbar spine, from L2 to S1, for the treatment of degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis.
• In January 2023, Notogen, Inc. announced that it had entered a worldwide research collaboration and license agreement with Boehringer Ingelheim to develop and commercialize a Notogen regenerative therapeutic that has the potential to become a first-in-class, disease modifying treatment for people living with degenerative disc disease (DDD).

 

Request a sample and discover the recent breakthroughs happening in the Degenerative Disc Disease pipeline landscape @ Degenerative Disc Disease Pipeline Outlook

 

Degenerative Disc Disease Overview

Degenerative Disc Disease (DDD) is a common condition that affects the intervertebral discs in the spine, causing them to deteriorate over time. These discs act as cushions between the vertebrae, allowing for flexibility and absorbing shock during movement. However, with age or due to other factors, the discs may undergo wear and tear, leading to DDD. The primary cause of Degenerative Disc Disease is the natural aging process. As people grow older, the discs lose water content, becoming less flexible and more prone to damage. 

The symptoms of DDD can vary depending on the location and severity of the affected discs. Common signs include chronic low back pain that worsens with prolonged sitting or bending and improves with lying down. Pain may also radiate to the buttocks, thighs, and legs, indicating potential nerve compression. Muscle weakness, numbness, and tingling sensations can also accompany the pain, affecting daily activities and mobility. 

Diagnosing Degenerative Disc Disease usually begins with a comprehensive medical history and physical examination by a healthcare professional. They will inquire about the patient’s symptoms, risk factors, and any relevant medical history. Imaging tests such as X-rays, MRI, or CT scans are crucial for visualizing the condition of the intervertebral discs and identifying any abnormalities.

 

Find out more about Degenerative Disc Disease medication @ New Drug for Degenerative Disc Disease 

 

Degenerative Disc Disease Treatment Analysis: Drug Profile

SB-01: Spine BioPharma, Inc.

SB-01 is a 7-amino acid peptide that binds to TGF1 and inhibits its action. TGF1 is an inflammatory cytokine that is frequently overexpressed in deteriorated discs. High TGF1 levels in a degenerative disc are connected with inflammation, pain medication, and extracellular matrix degradation, causing the disc to lose structural integrity. SB-01 treatment consists of a single intradiscal injection of the diseased disc and antagonizes TGF1 overexpression, which reduces inflammation, and pain medication, and increases extracellular matrix synthesis, which improves the structural integrity of the sick disc. It is now in the Phase III stage of clinical trial evaluation for the treatment of Degenerative Disc Disease.

 

BRTX-100: BioRestorative Therapies

BRTX-100 is a medication made from autologous cultivated mesenchymal stem cells derived from the patient’s bone marrow. The device will be used for the non-surgical treatment of painful lumbosacral disc problems, according to the company. The BRTX-100 manufacturing method involves extracting a patient’s bone marrow, isolating and cultivating stem cells from the bone marrow, and cryopreserving the cells. A physician will inject BRTX-100 into the patient’s injured disc during an outpatient surgery. The treatment is meant for people whose pain has not been relieved by non-invasive techniques and who may need surgery.

 

Key Degenerative Disc Disease Therapies and Companies

• SB-01: Spine BioPharma, Inc
• Rexlemestrocel-L: Mesoblast, Ltd.
• BRTX-100: BioRestorative Therapies
• Lorecivivint: Biosplice Therapeutics
• CWT 002: Causeway Therapeutics

 

Learn more about the novel and emerging Degenerative Disc Disease pipeline therapies @ Degenerative Disc Disease Clinical Trials

 

Degenerative Disc Disease Therapeutics Assessment

By Product Type

• Monotherapy
• Combination Therapy

By Stage

• Discovery
• Pre-Clinical
• Phase I
• Phase II
• Phase III
• Pre-registration

By Route of Administration

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

By Molecule Type

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

 

Scope of the Degenerative Disc Disease Pipeline Report 

• Coverage: Global 
• Key Degenerative Disc Disease Companies: Spine BioPharma, Inc., Angitia Biopharmaceuticals, Mesoblast, Ltd., BioRestorative Therapies, DiscGenics, Inc., Biosplice Therapeutics, Notogen, AnGes, Inc., FibroGenesis, Genequine Biotherapeutics, Causeway Therapeutics, Boehringer Ingelheim, SpineOvations, BIOPHARM GmbH, Yuhan, Histogen Inc., and others.
• Key Degenerative Disc Disease Pipeline Therapies: SB-01, AGA111, Rexlemestrocel-L, BRTX-100, IDCT, Lorecivivint, AMG0103, CybroCell,  GQ-401, CWT 002, DiscSeal, rhGDF-5, HST 004, and others.

 

Dive deep into rich insights for drugs used for Degenerative Disc Disease treatment; visit @ Degenerative Disc Disease Drugs 

 

Table of Contents

1.	Introduction
2.	Executive Summary
3.	Degenerative Disc Disease Pipeline: Overview
4.	Analytical Perspective In-depth Commercial Assessment
5.	Degenerative Disc Disease Pipeline Therapeutics
6.	Degenerative Disc Disease Pipeline: Late Stage Products (Phase III)
7.	Degenerative Disc Disease Pipeline: Late Stage Products (Phase III)
8.	Degenerative Disc Disease Pipeline: Mid-Stage Products (Phase II)
9.	Degenerative Disc Disease Pipeline: Early Stage Products (Phase  I)
10.	Degenerative Disc Disease Therapeutic Assessment
11.	Inactive Degenerative Disc Disease Products
12.	Company-University Collaborations (Licensing/Partnering) Analysis
13.	Key Degenerative Disc Disease Companies
14.	Key Degenerative Disc Disease Products
15.	Unmet Needs
16.	Degenerative Disc Disease Market Drivers and Barriers
17.	Future Perspectives and Conclusion
18.	Analyst Views
19.	Appendix

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting